Heterologous Ad.26.COV2.S versus homologous BNT162b2/mRNA-1273 as a third dose in solid organ transplant recipients seronegative after two-dose mRNA vaccination

Teresa P.Y. Chiang, Jennifer L. Alejo, Jonathan Mitchell, Jake D. Kim, Aura T. Abedon, Andrew H. Karaba, Letitia Thomas, Macey L. Levan, Jacqueline M. Garonzik-Wang, Robin K. Avery, Andrew Pekosz, William A Clarke, Daniel S. Warren, Aaron A.R. Tobian, Allan B Massie, Dorry L. Segev, William A. Werbel

Research output: Contribution to journalArticlepeer-review

Abstract

Heterologous vaccination (“mixing platforms”) for the third (D3) dose of SARS-CoV-2 vaccine is a potential strategy to improve antibody responses in solid organ transplant recipients (SOTRs), but data are mixed regarding potential differential immunogenicity. We assessed for differences in immunogenicity and tolerability of homologous (BNT162b2 or mRNA-1273; D3-mRNA) versus heterologous (Ad.26.COV2.S; D3-JJ) D3 among 377 SARS-CoV-2-infection naïve SOTRs who remained seronegative after two mRNA vaccines. We measured anti-spike titers and used weighted Poisson regression to evaluate seroconversion and development of high-titers, comparing D3-JJ to D3-mRNA, at 1-, 3-, and 6 month post-D3. 1-month post-D3, seroconversion (63% vs. 52%, p =.3) and development of high-titers (29% vs. 25%, p =.7) were comparable between D3-JJ and D3-mRNA recipients. 3 month post-D3, D3-JJ recipients were 1.4-fold more likely to seroconvert (80% vs. 57%, weighted incidence-rate-ratio: wIRR = 1.101.401.77, p =.006) but not more likely to develop high-titers (27% vs. 22%, wIRR = 0.440.921.93, p =.8). 6 month post-D3, D3-JJ recipients were 1.41-fold more likely to seroconvert (88% vs. 59%, wIRR = 1.04 1.411.93, p =.029) and 2.63-fold more likely to develop high-titers (59% vs. 21%, wIRR = 1.382.635.00, p =.003). There was no differential signal in alloimmune events or reactogenicity between platforms. SOTRs without antibody response after two mRNA vaccines may derive benefit from heterologous Ad.26.COV2.S D3.

Original languageEnglish (US)
Pages (from-to)2254-2260
Number of pages7
JournalAmerican Journal of Transplantation
Volume22
Issue number9
DOIs
StatePublished - Sep 2022
Externally publishedYes

Keywords

  • SARS-CoV-2
  • antibodies
  • heterologous
  • transplant
  • vaccine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Heterologous Ad.26.COV2.S versus homologous BNT162b2/mRNA-1273 as a third dose in solid organ transplant recipients seronegative after two-dose mRNA vaccination'. Together they form a unique fingerprint.

Cite this